At the recent European Association of Nuclear Medicine meeting in Barcelona, researchers from the British Columbia Cancer Research Institute and the University of British Columbia reported the development and preclinical evaluation of bispecific radiotracers designed to target prostate-specific membrane antigen (PSMA) and fibroblast activation protein (FAP).
Researchers from Almirall SA and affiliated organizations reported the discovery and preclinical characterization of LAS-200813, a novel peptide inhibitor of the Keap1-Nrf2 protein-protein interaction.
Researchers from Consejo Superior de Investigaciones Cientificas (CSIC) and affiliated organizations presented the discovery of a novel series of compounds acting as Ebola virus (EBOV) entry inhibitors.
Researchers from Anacor Pharmaceuticals Inc. and Pfizer Inc. have published preclinical data for the novel benzoxaborole prodrug AN-15368, being developed for the treatment of Chagas disease.
Polycomb repressive complex 2 (PRC2) is composed of several subunits, such as EZH2, EED and SUZ12, and is a regulator of cell proliferation and development. Targeting the allosteric subunit EED may be a new approach for fully inhibiting PRC2 complex activity and addressing the limitations of EZH2 inhibition.
Researchers from Guangzhou Medical University (GMU) described the discovery of a novel proteasome inhibitor NIC-0102, being developed as an anti-inflammatory therapeutic candidate.
RSS
